Browsing by Author "None Vikas"

Now showing 1 - 2 of 2

Chitosan-g-estrone Nanoparticles of Palbociclib Vanished Hypoxic Breast Tumor after Targeted Delivery: Development and Ultrasound/Photoacoustic Imaging
(American Chemical Society, 2023) Abhishesh Kumar Mehata; Virendra Singh; None Vikas; Nitesh Singh; Abhijit Mandal; Debabrata Dash; Biplob Koch; Madaswamy S. Muthu
Breast cancer is the leading cause of death among women globally. Approximately 80% of all breast cancers diagnosed are overexpressed with estrogen receptors (ERs). In this study, we have developed an estrone (Egen)-grafted chitosan-based polymeric nanocarrier for the targeted delivery of palbociclib (PLB) to breast cancer. The nanoparticles (NPs) were prepared by solvent evaporation using the ionic gelation method and characterized for particle size, zeta potential, polydispersity, surface morphology, surface chemistry, drug entrapment efficiency, cytotoxicity assay, cellular uptake, and apoptosis study. The developed PLB-CS NPs and PLB-CS-g-Egen NPs had a particle size of 116.3 ± 1.53 nm and 141.6 ± 1.97 nm, respectively. The zeta potential of PLB-CS NPs and PLB-CS-g-Egen NPs was found to be 18.70 ± 0.416 mV and 12.45 ± 0.574 mV, respectively. The morphological analysis demonstrated that all NPs were spherical in shape and had a smooth surface. An in vitro cytotoxicity assay was performed in estrogen receptor (ER)-expressing MCF7 cells and T47D cells, which suggested that targeted NPs were 57.34- and 30.32-fold more cytotoxic compared to the pure PLB, respectively. Additionally, cell cycle analysis confirmed that cell cycle progression from the G1 into S phase was blocked more efficiently by targeted NPs compared to nontargeted NPs and PLB in MCF7 cells. In vivo pharmacokinetic studies demonstrated that entrapment of the PLB in the NPs improved the half-life and bioavailability by ∼2-3-fold. Further, ultrasound and photoacoustic imaging of DMBA induced breast cancer in the Sprague-Dawley (SD) rat showed that targeted NPs completely vanished breast tumor, reduced hypoxic tumor volume, and suppressed tumor angiogenesis more efficiently compared to the nontargeted NPs and free PLB. Further, in vitro hemocompatibility and histopathology studies suggested that NPs were biocompatible and safe for clinical use. © 2023 American Chemical Society.
Fluorescent Calcium Nanocluster-Driven Theranostic Nanoplatforms for Advanced Imaging and Therapy in Breast Tumor
(American Chemical Society, 2025) Abhishesh Kumar Mehata; Vivek Kumar Verma; Virendra Pratap Singh; Aseem Setia; None Vikas; Matte Kasi Viswanadh; Shivesh Sabbarwal; Manoj Kumar; Biplob Koch; Madaswamy Sona S Muthu
Biocompatible CaCO3 nanoclusters were prepared by using a simple biomineralization technique. Employing CaCO3 nanoclusters in breast cancer treatment provides an exciting avenue for theranostics, which merges precise imaging with individualized treatment plans. They were highly suitable for improving the efficacy and precision of breast cancer detection and therapy with minimal adverse effects due to their biocompatibility, controlled drug release, pH sensitivity, and adaptability. In our current study, we proposed a palbociclib (PBB)-loaded fluorescent calcium nanocluster-based redox-sensitive drug delivery system for efficient breast cancer imaging and therapy. The developed nanoparticles were analyzed for their morphology and various physicochemical properties. The particle sizes of the formulated FNC-PBB-CS-NPs (nonredox-sensitive) and FNC-PBB-CS-SS-NPs (redox-sensitive) nanoparticles were 150.2 ± 2.1 and 160.4 ± 1.4 nm, respectively. The zeta potential of nonredox-sensitive nanoparticles was measured to be +17.12 ± 1.34 mV, while the zeta potential of redox-sensitive nanoparticles was +14.32 ± 1.17 mV. The entrapment efficiencies of FNC-PBB-CS-NPs and FNC-PBB-CS-SS-NPs were determined to be 88.74 ± 2.34 and 89.26 ± 1.21%, respectively. FNC-PBB-CS-SS-NPs demonstrated quicker drug release at acidic pH compared to FNC-PBB-CS-NPs. The cytotoxicity assay conducted on MCF-7 and T-47D cells indicated that FNC-PBB-CS-NPs and FNC-PBB-CS-SS-NPs exhibited greater cytotoxicities than free PBB. Furthermore, the Hoechst/PI dual-staining experiment demonstrated the superior activity of FNC-PBB-CS-SS-NPs over FNC-PBB-CS-NPs and free PBB. Ultrasound/photoacoustic imaging revealed that FNC-PBB-CS-SS-NPs effectively reduced tumor size, hypoxic tumor regions, and tumor vascularity compared to FNC-PBB-CS-NPs and free PBB. Additionally, in vivo optical imaging showed that the FNC-PBB-CS-SS-NPs accumulated more specifically in tumors than the other formulations. © 2025 American Chemical Society.